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Introduction
The availability of large, real world datasets has been 
essential in accelerating health data research, including 
the use of routinely collected data to drive new dis coveries 
and innovations. Many of these innovations use advanced 
statistical and computational methods, such as machine 
learning (ML).1,2 These include the development of algo­
rithms for the detection of breast cancer from mam 
mography, skin cancer from photographs, pneu monia 
from chest radiographs, and diabetic retinopathy from 
retinal fundus images, among many others.3–7 ML has also 
found many applications within ophthalmology, which 
include image segmentation, automated diagnosis, disease 
pre diction, and prognostication. Ophthalmology is particu­
larly suitable for ML because of the crucial role of imaging, 
where fundus photo graphs, optical coherence tomography 
(OCT), anterior segment photographs, and corneal topo­
graphy can be applied to conditions such as diabetic 
retinopathy, age­related macular degeneration, glaucoma, 
papilloedema, and cataracts.8–14
High­quality health data research and the development 
of ML models requires meaningful data at a sufficient 
scale. Such data undoubtedly exist. Most health insti­
tutions hold clinical imaging data at a scale ranging from 
tens of thousands to tens of millions of scans. However, 
these data are often inaccessible to resear chers, even 
where there is an intention to make them available for 
research, because of barriers of access and usability. 
Barriers of access can include: governance barriers (diffi­
culties in understanding and working through gov ernance 
frame works regulating data usage); cost barriers (there 
can be considerable overhead costs to datasets and many 
datasets require payment for access); and time barriers 
(dataset requests and curation might incur a considerable 
time lag before they can be made available). Barriers of 
usability include: data format barriers (the data might not 
be in a computationally tractable form); data quality 
barriers (the data might be of insufficient or uncertain 
quality); and image labelling barriers (most imaging pro­
jects depend on the accurate labelling of those images, 
which might not be undertaken as part of routine care and 
are difficult to do retrospectively. To bypass these bar riers, 
many research groups resort to using publicly available 
imaging datasets. This alternative route often leads to the 
same datasets within a clinical area being used by many 
research groups. Several wellknown public ophthalmo­
logical imaging data sets have been used multiple times by 
ML researchers, including MESSIDOR, DRIVE, 
EyePACS, and E­ophtha.15–18
Currently, there is no centralised directory of ophthal­
mological datasets and therefore little knowledge regard 
ing the amount of ophthalmological imaging data that 
are publicly available. It is also unclear what their acc­
essibility is, and how complete the reporting is of asso­
ciated metadata describing the image characteristics, the 
populations, and the diseases. This Review aims to 
identify all publicly available ophthalmological imaging 
datasets, to create a central directory of what is available 
for access currently. We report the source of each dataset, 
their accessibility, and a summary of the populations, 
diseases, and ima ging types represented.
Methods
Search strategy and selection criteria
This Review forms part of The Lancet Global Health 
Commission on Global Eye Health, which is examining 
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some of the central issues in global eye health.19 Any form 
of ophthalmological imaging was eligible for inclusion. 
Datasets containing non­ophthalmological images, text, 
or numerical­only data and images from non­human 
patients were excluded. No datasets were excluded on the 
basis of age, sex, or ethnicity of the patients from whom 
data were collected. Datasets of all languages and 
geographical origin were included.
The search consisted of two parts. First, we did a 
literature search of MEDLINE to identify studies de 
scribing ophthalmological imaging datasets that were 
publicly available and then attempted to access the 
data sets at source. The search combined terms 
describing various types of ophthalmological imaging, 
such as “eye”, “fundus”, and “retina”, with “optical 
coherence tomography”, “retinal images”, “biometry”, 
and “topography”, as well as terms such as “dataset” 
and “databases”. The MEDLINE search strategy is 
provided in the appendix (p 1). Second, we did a targeted 
search with similar search terms using Google’s Dataset 
Search and the Google search engine, to identify 
ophthalmological imaging datasets directly. Google’s 
Dataset Search is designed specifically for the discovery 
of online repositories and supports locating tabular, 
imaging, and text datasets. Additionally, indexing is 
provided to those interested in publicising their dataset 
with a metadata reference schema. For all the results 
returned from the search, it provides a description of 
the dataset content, direct links, and the file format. 
The Google searches also included terms relating to 
ocular diseases and ophthalmological imaging, and 
terms relating to datasets. For both the Google search 
and the Google Dataset searches, results returned from 
the first ten pages for each search were systematically 
collated and screened. The choice of ten pages was 
tested on the basis of several pilot searches at the 
beginning of this study to estimate the number of pages 
needed to capture the relevant results.
Our search was additionally supplemented by manually 
screening the references of relevant articles, the pro­
ceedings of relevant meetings, and consulting clinical 
experts in the field. The original search for all three 
sources, including all results from MEDLINE database 
inception, was done on Dec 3, 2019, and the MEDLINE 
search was updated on May 11, 2020. No restrictions were 
placed on language. Because of the absence of time­
stamping for Google searches, we were unable to update 
the Google searches.
Identification of ophthalmological imaging datasets
Search results from MEDLINE were screened by the 
primary reviewer (SMK) to identify the name and source 
of any relevant datasets. Where status of availability was 
unclear, we included these datasets and attempted 
to access their source, reporting any further barriers to 
access in our results. The Google and Google Dataset 
Search results were also screened by the primary reviewer 
to directly identify relevant datasets. Where there was 
ambiguity regarding whether a dataset fit the inclusion 
criteria, a second reviewer (XL) independently reviewed 
the dataset and if this could not be resolved, a third 
reviewer (SN) was consulted.
Dataset access and description
Various classifications have been proposed for levels of 
data accessibility, including a tiered grading system 
where data accessibility is described as open, safe­
guarded, or controlled.20,21 In this Review, we defined 
the accessibility of datasets as either: (1) open access, 
for which there were no requirements or minimum 
requirements for access (eg, submission of personal 
information, an email request, creation of an account); 
(2) open access with barriers, which were datasets 
fulfilling the theo retical criteria for open access, but 
being inaccessible because of unpredictable reasons 
(eg, no response to requests or broken hyperlinks); and 
(3) regulated access, which required the fulfilment of 
formal agreements, approvals, or payment. For the 
open access category where the dataset access required 
an email request, we allowed a 2­week period for email 
response; where the website was unresponsive or the 
download link was not functional, this was checked by a 
second and third reviewer, before the attempt to access 
was abandoned.
Extraction of dataset characteristics
A prespecified data extraction form was developed and 
piloted on the first 20 datasets (by SMK and XL). Infor­
mation characterising each dataset was recorded, including 
the direct links to the data source, accessibility, content (in 
terms of popu lation, pathology, and imaging), and 
associated metadata (inclu ding clinical data, image labels, 
and segmentation). Where this information was reported 
at source (eg, on the dataset website) or a link to the paper 
describing the dataset was provided, we recorded the 
information as provided. Additionally, we presented the 
completeness of the reporting for key clinical metadata 
items across all open access datasets. Each item was 
marked as reported if the information was described in the 
dataset documentation, description, or referencing publi­
cation and was accepted as reported even if given at the 
aggregate level.
Results
Datasets identified from the literature search
The MEDLINE search identified 3542 articles, of which 
2361 were deemed not relevant on the basis of screening 
their title and abstract. 1181 studies were obtained as full 
text articles, to be screened for the mention of ophthal­
mological imaging datasets that are publicly available. Of 
these, 534 records did not describe the datasets as publicly 
available and 151 reported non­ophthalmological datasets. 
Of the 496 articles that were still included, 161 potential 
datasets were identi fied. The same datasets were often 
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referenced by multiple studies. The targeted search 
for datasets with the use of Google’s Dataset Search 
and Google search engine identified 106 datasets and 
after combining the results, 81 duplicate datasets were 
removed and 46 datasets were further excluded (35 not 
fitting the inclusion criteria and 11 were derived from 
other included datasets). 140 unique datasets were 
identified and included for further assessment at the data 
source. The dataset selection process is outlined in 
figure 1.
Dataset access
Of the 140 unique datasets, only 94 were open access from 
which the raw data could be downloaded. 27 datasets were 
categorised as open access with barriers, from which data 
could not be downloaded. 19 datasets had regulated access 
(12 requiring licensing agreements, six requiring an 
ethical committee or institutional approval, and one 
requiring a payment of £2250 plus value­added tax).22 
Only the 94 open access datasets could be tho roughly 
characterised from inspection of the raw data themselves. 
Details of the datasets in the open access with barriers 
and regulated access categories are included in the 
appendix (pp 2–3) and are derived from information 
found at the source or in the description of the dataset in 
its associated publication, or both, rather than inspection 
of the raw data itself.
Characteristics of accessible datasets
Of the 94 open access datasets, we found 25 to be from 
within Asia (four from south Asia and 21 from southeast 
Asia or east Asia), nine from North Africa and the Middle 
East, 34 from Europe, 16 from North America, two from 
South America, and one from sub­Saharan Africa 
(figure 2). Of these, 9 datasets contained images origi­
nating from multiple countries. No data was reported to 
be originating from Oceania. The country of origin was 
unknown in 13 datasets. Dataset inception was reported 
by 47 datasets and ranged from 2003 to 2019. Open access 
dataset characteristics are summarised in the table.
From the 94 datasets, we were able to access 
507 724 images and 125 videos from at least 122 364 patients 
(39 datasets did not record the number of patients). The 
number of patients across the datasets ranged from two to 
85 550 (median=50; IQR=371), and the number of images 
ranged from eight to 109 312 (median=220; IQR=1017). The 
exact number of images could not be established for one 
dataset (CASIA Iris Ageing), so a conservative estimate 
was calculated from the dataset description (n=26 038). Of 
the total number of images, over half were contributed by 
three of the largest datasets: Kermany and colleagues 
(109 312 images),5 EyePACS (88 702 images),23 and MRL 
Eye (84 898 images).24 In contrast with these large datasets, 
68 datasets had less than 1000 images, each ranging from 
eight to 850 images (median=111; IQR=245).
Where reported, the most common reason for image 
acquisition was for a research study or a clinical trial 
(54 of 94; 57%), and for routine clinical care or screening 
(23 of 94; 24%). Five of 94 (5%) datasets included images 
acquired from primary care (including screening pro­
grammes), 45 of 94 (48%) were from secondary care 
(hospital or eye clinics), 18 of 94 (19%) were collected in 
other settings (such as from a university, research settings, 
or eye banks), and one of 94 (1%) from a non­health­care 
Figure 1: Dataset identification through MEDLINE articles, Google’s Datasets Search, and the Google search 
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setting. The setting was unreported in 25 of 94 (27%) 
datasets. Only 20 of 94 (21%) datasets gave information on 
whether patient consent was sought and 26 of 94 (28%) 
datasets stated details about obtaining ethical approval for 
obtaining or sharing the images.
Ophthalmological diseases represented in the datasets 
include diabetic eye disease (35 of 94; 37%), glaucoma 
(19 of 94; 20%), age­related macular degeneration 
(15 of 94; 16%), hypertensive retinopathy (six of 94; 6%), 
cataracts (four of 94; 4%), other eye diseases (the full list 
can be found in the table), and healthy eyes (58 of 94; 
62%; figure 2). Moreover, 17 of 94 (18%) datasets did not 
specify the diseases represented in the dataset. It is 
possible that these datasets contained healthy eyes; 
however, no specific indication was given at the data 
source. 53 of 94 (56%) datasets contained more than one 
disease, including healthy eyes. Healthy eye images were 
intended for use in a range of biomedical applications, 
such as the analysis of normal anatomical structures 
(including endothelial cell density, the detection of 
photoreceptors, the assessment of nerves, and vessel 
morphology) and for technical uses (including denoising 
images, iris recognition, and eye tracking).
Imaging modalities included in the datasets included 
retinal fundus photographs (54 of 94; 57%), OCT or OCT 
angiography (18 of 94; 19%), external eye photographs 
(seven of 94; 7%), in vivo confocal microscopy (five of 94; 
5%), scanning laser ophthalmoscopy and adaptive optics­
scanning laser ophthalmoscopy (five of 94; 5%), 
fluorescein angiography (four of 94; 4%), slit lamp 
photographs (one of 94; 1%), phase contrast microscopy 
(one of 94; 1%), specular microscopy (one of 94; 1%), 
preocular tear film photograph (one of 94; 1%), and videos 
(two of 94; 2%; figure 2). Of these, five datasets contained 
images taken from more than one modality. Of the 
18 imaging datasets based on OCT, half contained 
2 dimensional imaging data and the other half contained 
3 dimensional imaging data. Most datasets stored images 
in a portable network graphics, a tagged image file format, 
a bitmap image file, or a joint photographic experts group 
file format (82 of 94; 87%), ten of 94 (11%) datasets offered 
images as a Matlab file, one dataset offered a NumPy 
array file (Python), one dataset offered a portable pixmap 
format file (Netpbm) and 1 dataset offered a hierarchical 
data format file. Of these, nine of 94 (10%) datasets 
included images stored in multiple formats. 55 of 
94 (59%) datasets included images annotated with labels 
(including diagnostic labels, eg, grade of diabetic 
Figure 2: Information associated with the publication date (A), geographical 
distribution (B), represented diseases (C), and image types (D) of the study 
datasets
AO-SLO=adaptive optics-scanning laser ophthalmoscopy. OCT=optical 
coherence tomography. OCT-A=optical coherence tomography-angiography. 
SLO=scanning laser ophthalmoscopy. *Only diseases represented in ≥5 datasets 
have been included. Where datasets included multiple diseases, they are 
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retinopathy severity; or feature labels, eg, vessel labelled 
as an artery or vein) and 33 of 94 (35%) datasets included 
images annotated with manual segmentation, with 
14 of 94 (15%) datasets pro viding both labels and 
segmentation. Annotations were provided by an array of 
experts including ophthalmology clinicians, general 
medical physicians, and researchers (including medical 
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experts, or ground truth labellers). In addition, 15 datasets 
presented the images readily divided into either a training 
subset or a testing subset; however, they do not specify 
whether splits were made at the patient level.
Completeness of metadata reporting
The percentage of completion of the reporting for metadata 
items are shown in figure 3. Although technical details 
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rep orted, any associated clinical information was not. The 
following information was consistently reported across all 
datasets: imaging modality (100%), number of images 
(100%), image format (100%), country of origin (86%), 
device name and manufacturer (85%), and ophthal­
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age, sex, and ethnicity) were particularly under­reported 
(these factors were reported in <20% of datasets), with 74% 
of the datasets not reporting any patient demographic data, 
even at the aggregate level. The inclusion and exclusion 
criteria were described for only 15% of the datasets and the 
data collection period was reported for only 19% of the 
datasets. The completeness of the metadata reported by 
each dataset is summarised in the appendix (pp 4–7).
Discussion
Summary of findings
To the best of our knowledge, this is the first study to 
curate a comprehensive list of ophthalmological 
imaging data that are publicly available. From a search 
of the medical literature and dataset search engines, our 
Review found 94 unique ophthalmological datasets that 
fit in the open access category, containing over 
500 000 images. Besides healthy eyes, the most common 
diseases represented were diabetic retinopathy, glau­
coma, and age­related macular degeneration. These dis­
eases are most likely representative of the most 
commonly imaged dis eases in routine clinical practice 
and research. In particular, screening programmes for 
diabetic retinopathy exist in several countries, leading to 
the accumulation of large national­level imaging data of 
the diabetic population.25–27
Across all datasets, fundus retinal photography was 
the most common imaging type (54 of 94 datasets), prob 
ably because of its widespread availability and common 
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Table: Characteristics of the open access datasets
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The second most common imaging modality was OCT 
and OCT angiography (18 of 94 datasets, where 9 
contained 3 dimensional OCT data). Preservation of the 
3 dimensional volume data is advantageous as they give 
contextual information from neighbouring B­scans, 
allowing ML algorithms to learn key structural infor­
mation that might enhance its performance.
Several variables that are clinically essential were 
under­reported across all datasets. Demographic data 
including age, sex, and ethnicity were not reported in 
most of the datasets (74%), even at the aggregate level. 
Furthermore, inclusion and exclusion criteria were only 
defined for 15% of the datasets. This missing information 
is a concern as it is unclear whether there is appropriate 
representation of population groups within the data, and 
the ability of researchers to assess the applicability to 
research findings from these data will be severely res­
tricted.
For datasets with image labels (such as diagnostic or 
feature labels), the labelling processes were also poorly 
defined. Many assumptions are made during the label­
ling of ground truths, and therefore assurance regar ding 
the label accuracy are paramount since they carry 
implications for any ML model trained with the use of 
these labels. Details about the labellers’ amount of exper­
tise, the consensus process used for multiple labellers, 
and how discrepancies were resolved are therefore all 
relevant.28 In the few datasets that reported this infor­
mation, labellers ranged from medical students to 
specialist ophthalmologists, but in most cases the skills 
of the labellers were unknown. Although the detailed 
labelling of public datasets might be ambitious, a check­
list of minimum reporting metadata items could dras­
tically improve the usefulness of the data and could also 
potentially enable merging across multiple datasets.
Strengths and weaknesses
This is the first study to systematically identify ophthal­
mological imaging datasets that are publicly available. 
An important aspect of the work is the unrestrictive 
nature of the search strategy applied to a medical biblio­
graphic dataset and online search engines, including 
those specifically targeting datasets. This method recog­
nises the possibility that not all relevant datasets would 
be identified with the use of academic publications alone. 
Furthermore, we sought to verify the claims of all 
datasets, so that we could adjudge the extent to which 
such datasets were truly open access and what the user 
experience might be. We took reasonable measures to 
obtain actual copies of the data, so their contents could 
be examined and verified. This process gave us the ability 
to identify accessibility barriers where data described as 
being open access were difficult to access regardless. 
This process also enabled us to identify the extent to 
which key metadata were available.
We recognise several limitations to our study. Firstly, 
only the initial ten pages of results returned by a Google 
Dataset search and Google’s search engine results were 
screened. It is not clear how the ranking of datasets in 
Google Datasets Search is established, but according to 
the documentation, metadata quality, the number of 
citations, and a combination of other factors are taken into 
account.29 The nature of the Google search engines is such 
that it is not possible to update the searches, whereas the 
MEDLINE search was originally run in December, 2019 
and could be updated in May, 2020. Given the probable 
delays between a dataset being publicly available, and a 
study being completed and becoming visible on 
MEDLINE, it would be reasonable to assume that our 
Review describes the situation as of December, 2019. 
Secondly, we recognise that this field is moving fast and 
that this Review is only a snapshot in time. Unlike 
publications, datasets can be edited, updated, and removed 
without documentation. As with the timestamping issue, 
these alterations prohibit the ability to monitor changes in 
data availability over time. Thirdly, there are other sources 
of datasets available, such as Kaggle, but these were not 
explored in this Review (although the Google Dataset 
Search tool explicitly indexes Kaggle). Future iterations of 
this study will explore other search engines beyond Google 
Datasets Search. Lastly, our aim was specifically targeted 
towards identifying open access datasets. As such, some 
datasets with regulated access might not have been 
identified if they were not described as being open access. 
If there were requirements for accessing the data, we took 
Figure 3: Percentage completion of reporting of metadata items across all 94 datasets
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reasonable measures to obtain actual copies. We emailed 
the authors or owners of the data (when requested) but did 
not go as far as completing licensing agreements or 
pursuing any ethical committee approvals. Although ver­
ification of access for those datasets would be wel come, 
doing so was outside the scope of this Review and would 
have imposed an additional burden on those institutions 
with little value other than simple verification. However, 
we do recognise that the datasets with regulated access 
might be of higher quality, and that this more res tricted 
access might reflect governance processes asso ciated with 
a stronger attention to quality and metadata reporting. 
Regardless, as noted earlier, ease and speed of access is an 
important driver for researchers, and there is a risk that 
the benefits of a higher quality dataset might be overlooked 
in favour of a lower quality dataset that has immediate, 
unregulated access.
Implications
Publicly available imaging datasets are increasingly being 
used by a range of researchers from epidemiologists to 
computer scientists. These datasets can be a powerful 
enabler to research but, as with any data source, the 
provenance and limitations of that dataset must be 
considered. In this section, we highlight three broad 
implications for the providers and users of such datasets: 
accessibility; transparency and reporting; and ensuring an 
adequate representation of the population.
The first implication is accessibility. It is encouraging 
that our Review identified 94 data sets that were potentially 
open access, but discoverability appears to be an issue. 
Although a few datasets are well known, many are not, 
which might lead to lost research opportunities and might 
result in bias because of an overuse of a few potentially 
non­repre sentative datasets. There is value in having an 
online catalogue of such datasets, which would improve 
their visibility and provide some key metadata that would 
enable researchers to identify the most suitable dataset for 
their research question. Our study provides an initial 
point of access that will improve their discoverability. 
Further considerations in this regard, arising from our 
Review, include a greater clarity around the terms of 
access from some dataset providers. Although it was 
beyond the scope of this study, such datasets should also 
be accompanied by sufficient information regarding their 
provenance so that researchers can be assured that there 
is an appropriate ethical and governance framework 
underpinning the provision of these data.
The second important implication is the transparency 
and reporting of a dataset. The value of a dataset is 
associated with far more than just its size, and our Review 
has highlighted many factors that would be key con­
siderations for a user. There are, of course, advantages to 
scale, for example in the development of deep learning 
models or when seeking to detect a modest signal in a 
heterogeneous population, but the usability of the dataset 
will also be associated with the quality, depth, and 
representativeness of the data. Small datasets such as 
DRIVE (consisting of only 40 images) are examples of a 
situation in which high­quality labelling and annotation 
outweighs quantity. DRIVE has become a popular 
resource for researchers for the purposes of retinal vessel 
segmentation, probably because of the richness and 
quality of the segmentation annotations.30,31 Given the 
need for researchers to show the generalisability of 
research findings and their clinical applicability, it is 
essential that these digital repositories are adequately 
representative of the diverse population of humans and 
their diseases. Important characteristics should be re 
p orted to assist the user in decisions around applicability. 
There is sparse reporting of data characteristics and little 
guidance to inform the curators of such datasets. Although 
these might be unimportant considerations from a 
technical perspective, they are crucial to consider for any 
clinical applications. Without key information about the 
population and disease, it is impossible to make assump­
tions on how generalisable the data are for a real world 
setting. Previous work outside of the field of health data, 
such as Datasheets for Datasets (a concept derived from 
the electronics industry), have previously highlighted 
many of the issues raised in this Review, which are 
prevalent across disciplines.32 Gebru and colleagues32 have 
proposed the reporting of considerations that can improve 
the transparency and accountability of datasets.
However, there are recognised challenges associated 
with pro viding richly labelled data. The curation of 
metadata items is demanding, costly, and requires careful 
con sideration to ensure accuracy and completeness. The 
excessive inclu sion of detailed metadata could also 
increase the chance of the reidentification of data items 
and pose additional privacy concerns. Therefore cur ation, 
storage, and access all require thoughtful ethical oversight. 
How ever, these risks should be balanced with the potential 
harm implicated by widespread use of biased and clinically 
unusable data. Additionally, the risk of reidentification can 
be mitigated with adherence to widely adopted guidelines 
for the sharing of raw clinical trial data.33 The investment 
of time, skill, and money would generate substantial value 
in the data and its associated labels, therefore such a 
dataset is unlikely to be freely available.
The last key implication is around ensuring adequate 
representation of the population by such datasets. A 
major concern is the possibility of the underrepresentation 
of specific groups within public and other datasets, 
posing unknown biases towards some populations or 
disease groups. An ML algorithm developed exclusively 
on one population group might translate poorly beyond 
that population.34 If an ML algorithm runs poorly on 
unseen data that are inadequately described, it is difficult 
to establish whether the poor performance is attributable 
to spectrum bias.35–37 Knowledge of the populations repre­
sented is therefore important for the development of ML 
algorithms and even more so for their evaluation. This 
is a key consideration from a global perspective, as 
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countries wishing to develop applications where there is 
no infrastructure to curate imaging datasets might also 
be most likely to access publicly available resources as a 
first option.
Underrepresentation of diseases is also a concern. 
Datasets are likely to reflect diseases of particular rele­
vance to their country of origin; data from routine clinical 
care will reflect the prevalence of the disease of the 
attending population; and cohort data will reflect the 
inclu sion criteria of the study, but also the health priorities 
of that particular country. The type of diseases within each 
dataset and their prevalence within the dataset will affect 
the generalisability of that dataset to other settings 
globally. It is important to note that, of the priority eye 
diseases highlighted by WHO, only diabetic retinopathy, 
glaucoma, and age­related macular degen eration were 
strongly represented in the public imaging datasets. For 
2015, these three conditions together were estimated to 
account for 15% of global blindness and 5% of moderate 
and severe vision impairment, in contrast with the other 
priority diseases such as cataracts (four datasets), trachoma 
(one dataset), and refractive errors (three datasets), which 
contribute to 53% of blindness and 79% of moderate and 
severe vision impairment.38 This mismatch might be 
attributed to many factors, including the relative impor­
tance of imaging in the management of the disease, the 
presence of well developed screening programmes for the 
most rep resented diseases (such as diabetic retino pathy) 
and funding available for specific research areas. Diabetic 
retinopathy, glaucoma, and age­related macular degen­
eration are more frequently imaged as part of standard 
care, as opposed to cataracts, trachoma, and refractive 
errors. If potential imaging­based solutions could improve 
the care of patients with cataracts, trach oma, and refractive 
errors by a non­specialist workforce with the use of task 
sharing, then perhaps a targeted global effort is required 
to prioritise the curation and development of imaging in 
these disease areas.
The publicly available datasets identified in this Review 
are unevenly distributed globally. There are no known 
publicly available datasets for ophthalmological images 
in 172 countries (equating to nearly 3·5 billion people, or 
45% of the global population). The availability of needed 
data is even lower if specific use cases are considered. For 
understanding the healthy eye, there are 58 datasets from 
20 countries, representing 54% of the population; for 
age­related macular degeneration, there are 15 datasets 
from 6 countries, representing an estimated 44% of the 
population; for diabetic eye disease, there are 35 datasets 
from 14 countries, representing 50% of the population. 
Inferences from data cannot be assumed to generalise 
across populations and might be unusable on unseen 
populations. We would argue that this is a form of data 
poverty that should be taken seriously as it might cause 
widening of health inequalities, as major parts of the 
world are unable to benefit from innovations arising in 
a small pool of data­rich countries.
Conclusion
Publicly available datasets are potentially valuable assets 
for research and innovation in health care. Barriers to 
their use include poor visibility, issues of accessibility, or 
limited usability because of incomplete metadata, includ 
ing an absence of key parameters necessary for evalu­
ating the provenance, quality of data, and the diver sity of 
the population sampled. There is a danger that research 
ers use a small, skewed pool of data because there are 
only a few datasets that have high visibility, along with 
easy access and usability. In real world evi dence studies 
this might lead to substantial bias. In the deployment of 
artifical intelligence systems it might lead to a poor 
generalisability, with a risk of underperformance or even 
failure when trans ferred between settings and groups of 
people. We pro pose that this is a new form of data pov­
erty, where the scarce availability of representative 
datasets (public and other) will restrict the extent to 
which some individuals or even whole populations can 
benefit from digital health solutions and artifical 
intelligence systems. Here lies an opportunity to not only 
improve the visibility, accessibility, and usability of 
existing publicly available datasets, but also for health 
systems and researchers to invest in new publicly 
available datasets that can support research, innovation, 
and validation in areas that currently have few data.
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